Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 267

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

Open access
Nijhof, I S, Groen, R W J, Lokhorst, H M, van Kessel, B, Bloem, A C, van Velzen, J, de Jong-Korlaar, R, Yuan, H, Noort, W A, Klein, S K, Martens, A C M, Doshi, P, Sasser, K, Mutis, T, van de Donk, N W C J·2015·Leukemia

Abstract

Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple myeloma (MM) cells, including ADCC (antibody-dependent cellular cytotoxicity) and CDC (complement-dependent cytotoxicity). Owing to a marked heterogeneity of response to daratumumab therapy in MM, we investigated determinants of the sensitivity of MM cells toward daratumumab-mediated ADCC and CDC. In bone marrow samples from 144 MM patients, we observed no difference in daratumumab-mediated lysis between newly diagnosed or relapsed/refractory patients. However, we discovered, next to an expected effect of effector (natural killer cells/monocytes) to target (MM cells) ratio on ADCC, a significant association between CD38 expression and daratumumab-mediated ADCC (127 patients), as well as CDC (56 patients). Similarly, experiments with isogenic MM cell lines expressing different levels of CD38 revealed that the level of CD38 expression is an important determinant of daratumumab-mediated ADCC and CDC. Importantly, all-trans retinoic acid (ATRA) increased CD38 expression levels but also reduced expression of the complement-inhibitory proteins CD55 and CD59 in both cell lines and primary MM samples. This resulted in a significant enhancement of the activity of daratumumab in vitro and in a humanized MM mouse model as well. Our results provide the preclinical rationale for further evaluation of daratumumab combined with ATRA in MM patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2015.123

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 267

Metadata

Authors
Nijhof, I. S., Groen, R. W. J., Lokhorst, H. M., van Kessel, B., Bloem, A. C., van Velzen, J., de Jong-Korlaar, R., Yuan, H., Noort, W. A., Klein, S. K., Martens, A. C. M., Doshi, P., Sasser, K., Mutis, T., & van de Donk, N. W. C. J.
Venue
Leukemia
Published
2015-05-15
Volume
29
Issue
10
Pages
2039-2049
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W1600286956
Cited by
267
References
35
FWCI
14.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. https://app.cochat.ai/papers/10.1038/leu.2015.123
The paper
Nijhof, I. S., Groen, R. W. J., Lokhorst, H. M., van Kessel, B., Bloem, A. C., van Velzen, J., de Jong-Korlaar, R., Yuan, H., Noort, W. A., Klein, S. K., Martens, A. C. M., Doshi, P., Sasser, K., Mutis, T., & van de Donk, N. W. C. J. (2015). Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. https://doi.org/10.1038/leu.2015.123

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.